Release date: 2013-01-09
Good news came from the First Affiliated Hospital of Zhengzhou University: The vascular retractable stent developed by the hospital was approved to enter the clinic and became the first foreign peripheral vascular retractable stent to enter clinical application.
According to experts, at present, the treatment of vascular obstruction is mostly by balloon dilatation or permanent endovascular stent placement. However, after balloon dilatation, it is easy to re-stenosis, while permanent stent is stimulated by foreign body and vascular endothelial cells. Hyperplasia is again narrow. At the same time, the internal stent damages the vascular endothelial cells, exposes the thrombus formation of the subendothelial tissue, and causes a series of problems such as recurrence of the vascular stenosis. Therefore, the rate of restenosis of the peripheral vascular stent is as high as 25%, and the venous system is placed in the internal stent. The rate of restenosis is still high.
Experts said that for intravascular thrombosis or vascular stenosis with thrombosis, interventional treatment is mainly through intraoperative thrombectomy, thrombolysis and stent thrombectomy. Thrombolytic therapy is more suitable for fresh thrombus; stent thrombectomy is mainly suitable for the treatment of mixed thrombus, ie subacute or chronic thrombosis, but it is ideal because of the permanent stent placement of compression thrombus, which may block the blood vessel to cause restenosis. The method of radical vascular occlusion and thrombosis has been the goal of clinical research.
As early as 2006, the research team of the institute worked hard and repeated experiments to design a retrievable filter-type intravascular stent and obtained national patents. Since then, based on animal experiments, they have begun to experiment with clinical trials of reversible stent compression thrombosis. The clinical application of more than 10 patients confirmed the feasibility, safety and effectiveness of the technology. The preliminary research results were published in the American Journal of Thoracic Surgery.
Subsequently, the hospital expanded the clinical application study, and conducted a close follow-up study of all patients for 1 to 5 years, confirming the medium- and long-term safety and effectiveness of the inferior vena cava recoverable stent. The results of the study were published in the United States. Journal of Vascular and Interventional Radiology.
Source: Kexun
Biocide Technical Ingredients
All water based products have plenty of nutrients and water to support microbe growth under favorable conditions. Microbes invade water based products from multi-point sources, such as contaminated raw materials, poor plant hygiene, untreated water, and not properly preserved recycling materials. While adding in-can preservatives into the products should not excuse a factory from Good Manufacturing Hygiene Practices (GMHP), proper use of in-can preservatives coupled with GMHP can dramatically minimize the chance of microbial tolerance development, and assure unspoiled products to customers.
Biocides formulators often use several types of in-can preservatives as active ingredients in their biocidal products for various industrial water based products. One of these active ingredients is benzisothiazolone (BIT). It has several distinct performance advantages, including good stability at high pH, good stability in the presence of reducing agents, and broad spectrum of activities against many microbes.Sunshine Biotech supplies to all industrial biocides formulators with high quality BIT technical ingredients. Besides of BIT, we also provide its derivative, like BBIT, MBIT etc.
Biocide Technical Ingredients,Biocide Formula,Biocide Ingredients,Biocide Liquid
Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com